|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0023473,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0205197,
umls-concept:C0439234,
umls-concept:C0457454,
umls-concept:C0544452,
umls-concept:C0723457,
umls-concept:C0935989,
umls-concept:C1314677,
umls-concept:C1444662,
umls-concept:C1521991,
umls-concept:C1947925,
umls-concept:C2746065
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-11-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long term. We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:CharbonnierAudeA,
pubmed-author:EtienneGabrielG,
pubmed-author:GuerciAgnèsA,
pubmed-author:GuilhotFrançoisF,
pubmed-author:GuilhotJoëlleJ,
pubmed-author:HuguetFrançoiseF,
pubmed-author:Intergroupe Français des Leucémies Myéloïdes Chroniques,
pubmed-author:LegrosLaurenceL,
pubmed-author:MahonFrançois-XavierFX,
pubmed-author:NicoliniFranckF,
pubmed-author:RéaDelphineD,
pubmed-author:ReiffersJosyJ,
pubmed-author:RousselotPhilippeP,
pubmed-author:VaretBrunoB
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1029-35
|
|
pubmed:dateRevised |
2011-4-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20965785-Adult,
pubmed-meshheading:20965785-Aged,
pubmed-meshheading:20965785-Aged, 80 and over,
pubmed-meshheading:20965785-Antineoplastic Agents,
pubmed-meshheading:20965785-Drug Administration Schedule,
pubmed-meshheading:20965785-Female,
pubmed-meshheading:20965785-France,
pubmed-meshheading:20965785-Fusion Proteins, bcr-abl,
pubmed-meshheading:20965785-Gene Expression Regulation, Leukemic,
pubmed-meshheading:20965785-Humans,
pubmed-meshheading:20965785-Kaplan-Meier Estimate,
pubmed-meshheading:20965785-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:20965785-Male,
pubmed-meshheading:20965785-Middle Aged,
pubmed-meshheading:20965785-Piperazines,
pubmed-meshheading:20965785-Prospective Studies,
pubmed-meshheading:20965785-Protein Kinase Inhibitors,
pubmed-meshheading:20965785-Proto-Oncogene Proteins c-abl,
pubmed-meshheading:20965785-Pyrimidines,
pubmed-meshheading:20965785-Recurrence,
pubmed-meshheading:20965785-Remission Induction,
pubmed-meshheading:20965785-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20965785-Survival Rate,
pubmed-meshheading:20965785-Time Factors,
pubmed-meshheading:20965785-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
|
|
pubmed:affiliation |
Laboratoire d'Hématologie et Service des Maladies du Sang, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. francois-xavier.mahon@umr5540.u-bordeaux2.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
